Is the CSL (ASX:CSL) share price too cheap to ignore?

The CSL Limited (ASX:CSL) share price is down 21% from its 52-week high. Is this a buying opportunity for investors next week?

| More on:
ResMed share price healthcare asx share price flat represented by doctor shrugging

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It has been an unusually disappointing year for the CSL Limited (ASX: CSL) share price.

The biotechnology giant's shares have thoroughly underperformed the market during this time and are trading significantly lower than their 52-week high.

In fact, with the CSL share price currently fetching $263.40, it is down 21% from its high of $332.68.

Why is the CSL share price under pressure?

The weakness in the CSL share price has been driven largely by concerns over plasma collection headwinds.

As well as being impacted by social distancing initiatives, COVID stimulus payments have prevented some traditional donors from donating. This has led to a reduction in supply and an increase in costs.

Given how plasma is a vital component in many of CSL's most lucrative therapies, this has the potential to weigh on margins in the short term.

However, it is important to understand that this is a temporary headwind and not structural. In light of this, once the pandemic passes, plasma collections should become far easier and costs should inevitably reduce.

In the meantime, increased demand for influenza vaccines looks set to offset some of this headwind.

Another concern that appears to be weighing on investor sentiment is Argenx's FcRn CIDP therapy, which is under development. This has the potential to be a bit of a game changer in the industry and could steal away some immunoglobulin sales in the future.

Is this a buying opportunity?

A number of brokers believe that the CSL share price is trading at a very attractive level.

For example, UBS currently has a buy rating and $330.00 price target and Credit Suisse has an outperform rating and $315.00 price target.

UBS' price target implies potential upside of 25% over the next 12 months. Whereas Credit Suisse's price target represents upside of just under 20%.

It is also worth noting that the latter broker isn't worried about Argenx's FcRn CIDP therapy. Even if it were a success, the broker believes demand is growing strong enough to accommodate both therapies.

All in all, these brokers appear to believe that now would be an opportune time to buy CSL shares.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Blue Chip Shares

A young woman sits on a sofa in a stylish home with her laptop computer balanced on her knee and smiles with a satisfied look on her face at what she's seeing on the screen.
Blue Chip Shares

2 ASX blue-chip shares offering big dividend yields

These stocks could provide strong passive income.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Blue Chip Shares

3 ASX 200 blue chip shares to buy with $3,000 in July

Analysts have recently named these well-known stocks as top buys.

Read more »

Two people having a meeting using a laptop and tablet to discuss Seven West Media's balance sheet
Blue Chip Shares

3 fantastic ASX shares to buy for an SMSF

Let's see why these shares that brokers rate as buys could be top picks for super investors.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Blue Chip Shares

Buy these fantastic ASX 200 blue chips with $10,000

Analysts think these top stocks are buys right now.

Read more »

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Blue Chip Shares

The best ASX shares to buy and forget for 10+ years

Want to make long term investments? Here are three picks that brokers rate as buys.

Read more »

An ASX investor in a business shirt and tie looks at his computer screen and scratches his head with one hand wondering if he should buy ASX shares yet
Blue Chip Shares

This popular ASX 200 blue-chip share has literally gone nowhere in 17 years

Even blue-chip shares can fall short.

Read more »

Two smiling work colleagues discuss an investment or business plan at their office.
Blue Chip Shares

3 no-brainer ASX shares to buy now with $5,000

Brokers think these shares could be among the best to buy right now.

Read more »

Broker checking out the share price oh his smartphone and laptop.
Blue Chip Shares

2 ASX blue-chip shares offering big dividend yields

These businesses are predicted to pay significant passive income to shareholders.

Read more »